Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Hypertension and hyperuricaemia are widespread conditions. There is significant overlap
between the two conditions. Serum uric acid (SUA) is currently recognized as a risk factor
for cardiovascular disease. Thus, at some point in their therapy, hypertensive patients with
hyperuricaemia are likely to require concurrent treatment with anti-hypertensive and
hypouricaemic agents. For this reason, it is important to determine whether there are any
pharmacokinetic interactions resulting from the concomitant administration of such
agents.Olmesartan is an angiotensin II receptor antagonist and effective and well tolerated
in the treatment of arterial hypertension. Probenecid is a well-established hypouricaemic
agent for the treatment of hyperuricaemia and gout.The goal of this study was to examine the
impact of coadministration of probenecid on the pharmacokinetic parameters and tolerability
of olmesartan in healthy volunteers.